Introduction
============

Congenital nystagmus (CN) is a common oculomotor disorder with a frequency of 1/20,000 live births \[[@r1]\]. It is characterized by involuntary, rhythmical, repeated oscillations of one or both eyes with onset typically at birth or within the first few months of life. Patients' oscillations can be horizontal, vertical, torsional, or any combination of these, although horizontal is the most common \[[@r2]\].

CN is genetically heterogeneous. Two genes responsible for X-linked CN have been identified (i.e., G protein-coupled receptor 143 (*GPR143*) for X-linked ocular albinism

(XLOA) \[[@r3]\] and four-point-one (4.1), ezrin, radixin, moesin (FERM) domain-containing 7 (*FRMD7*) for X-linked CN-1 \[[@r4],[@r5]\]). The third X-linked form of CN has been mapped to Xp11.4-p11.3 \[[@r6]\].

Here, we report on a five-generation Chinese family with X-linked CN. Mutation analysis of the two candidate genes (*FRMD7* and *GPR143*) indicated that a novel splicing mutation of *GPR143* was responsible for the disease in this family.

Methods
=======

Patients
--------

The CN family studied here came from the Hunan province in the southern part of China and comprised five generations with nine affected members ([Figure 1](#f1){ref-type="fig"}). The proband (V:4) was referred to our clinic at the age of seven because of his horizontal CN in both eyes. After an uneventful 38-week pregnancy of the primigravid mother, he was born at a normal weight. Consanguinity was denied, and no chemical exposure or maternal drug use was noted during his mother's pregnancy. This study complied fully with the Tenets of the Declaration of Helsinki, and it was approved by the Ethics Board of the State Key Laboratory of Medical Genetics of China. Informed consent was given by all members of the family before testing.

![The Chinese CN pedigree. Black-filled symbols indicate patients who carried the novel mutation in the hemizygous state. Dot-marked symbols represent females who carried the mutation. The proband is marked by arrow.](mv-v17-715-f1){#f1}

Mutation screening
------------------

Genomic DNA was extracted from the peripheral blood using the standard phenol/chloroform method and stored at −20 °C. Mutation analysis of *GPR143* and *FRMD7* was performed using polymerase chain reaction (PCR) and direct sequencing. Primers were designed to cover the sequences of all exons and introns adjacent to each exon of *GPR143* and *FRMD7*, according to published primer sequences ([Table 1](#t1){ref-type="table"}) \[[@r7],[@r8]\]. PCR products were directly sequenced with an ABI PRISM BigDye kit (Carsbad, CA) using the same ampliﬁcation primers on an ABI3100 DNA sequencer (Carsbad, CA). Sequences were analyzed with the DNASTAR (Madison, WI) software.

###### Primers and PCR conditions used to amplify genomic segments of *GPR143* and *FRMD7*.

  **Primer name**   **Forward primer(5'-3')**   **Reverse primer(5'-3')**   **Annealing temperature (°C)**   **Product size (bp)**
  ----------------- --------------------------- --------------------------- -------------------------------- -----------------------
  *GPR143*-1a       CTCCTCCGCCCGCCCAAGCATCAC    CCCAGGCAGCCGAGAAGGTC        66                               464
  *GPR143*-1b       CCGCGCCTAGGGACCTTCTGCT      AACCCGCGGGCCTCTCGTCCTCAC    69                               399
  *GPR143*-2        CTTTCTTCCTTTTCCCTCCTTGTC    GTTTGCTGCTGCTGCGATTTG       61                               360
  *GPR143*-3        CACGTGCGGCTTCCTGAC          TTGGCCTCTTATAAAAATGA        59                               385
  *GPR143*-4        GGGCTTTCCTCTGTGTACATTTTC    CCCTGAGACAACGGCCTAACC       63                               334
  *GPR143*-5        GCATTTCCCTTTTTGTTCTCATCC    AGGCCTGCACATTTTCATTTATTG    61                               406
  *GPR143*-6        TTGCTTCCTGCCCCTCTGG         ACTTGCTCCCCTGTCCTCTGT       63                               400
  *GPR143*-7        TGCACCTGGCCCTCTTAGTTTC      TCAGGAGGCCAAGACAGAGGAT      63                               441
  *GPR143*-8a       AAACCAACCCACCAACCAGTCAAC    GCATGCTCAGGGCTTCGTCA        63                               395
  *GPR143*-8b       CCAGCCCAGGGATTTCTCTT        ACCCCGCCATGCACAGGAC         63                               329
  *GPR143*-9        AGCTGATGACAAACCTGCTAG       CCCTTTCTCCTATCCTAAAG        61                               330
  *FRMD7*-1         CCTTGGGTGTGCATTACTTC        TTTGCTATTGTTGTCCCTTGAG      57                               459
  *FRMD7*-2         AAACAACACAGAGACAGATAAGTGG   CAATCAGGGAATTGAACCCTAC      57                               385
  *FRMD7*-3         AGGCAGTGGAGCAGTGATTC        GCAGCATGATTTCTTTCATCTC      68                               499
  *FRMD7*-4         CTCGAAGGCAGAGAGGGTAG        CCCTTTGGATGATGAACACC        69                               519
  *FRMD7*-5         GGCACCATTCCTTTCTTGAAT       CAGGCCATGCTGTTTCTCTC        57                               350
  *FRMD7*-6         TTTGGACTGCATTGGCTACA        AGGATCTCAGCGTTTCATGG        57                               353
  *FRMD7*-7         TCATGCACTTTCATCAGAAGC       TGATTGACCATTTCCCTTTC        57                               497
  *FRMD7*-8         TGTGCAAGAGATGGGTCAAG        CTCTGGTTGATTTCTTCAAAGG      57                               368
  *FRMD7*-9         GCTCTGTTTGTGAGCAGTGG        AGGGTGCAATCTTTGATGTG        57                               495
  *FRMD7*-10        AGGTTGTTCTCTGCCTGGTC        GCACTGTCGTTCATGGTACTG       57                               398
  *FRMD7*-11        TGTTTCTCTTGCTCGTGTTGA       TTTTTACACACTGGGATTCTGG      57                               282
  *FRMD7*-12a       CCCTAGAATAGAACATGGATCTTG    TGGGATCAGGGTTAGGATTG        57                               388
  *FRMD7*-12b       CCTTCTTTCACCAATGTGTCC       AATACCAACCTGCTGACCTG        57                               452
  *FRMD7*-12c       CTTTAACACTGAGCCCAATC        TGACTGAGAGCAGGACAAGG        57                               588
  *FRMD7*-12d       ACGGATGTGCCCTATATTCC        GCAACTCCTGCTCTGCAAAC        57                               472
  *FRMD7*-12e       AGCCCAAGGAATATCAGAATG       GCAGTTGGTGTGTTGAAATAAGC     57                               500
  *FRMD7*-12f       GCTCTCAGTCATAAAGCAGACC      CCTTCAGAGGTAATGGAAGAGTG     57                               500

A total of 200 healthy, unrelated volunteers were recruited as controls, including 103 males and 97 females aged 10--60 years with an average age of 33. The novel splicing mutation of *GPR143* was tested in the 200 healthy controls by direct sequencing.

Results
=======

Clinical findings
-----------------

Nine males in three successive generations of the Chinese family were affected, indicating that the disease may be inherited in an X-linked recessive pattern in this family ([Figure 1](#f1){ref-type="fig"}). The proband presented with typical symptoms of CN, including nystagmus, amblyopia, foveal hypoplasia, and fundus hypopigmentation. Results of a computed tomography (CT) scan of the brain were normal in the proband.

### Nystagmus and reduced visual acuity

The nine patients all had nystagmus and poor visual acuity as a first symptom. The nystagmus was present during their first three months of life with a corrected visual acuity (VA) of 0.1--0.2. The proband's (V:4) nystagmus was sometimes associated with head nodding, and the amplitude varied with horizontal gaze position. In all patients, the nystagmus had a tendency to diminish with age, while it rarely disappeared completely (e.g., the proband's grandfather (III:5) continued to experience nystagmus even at age 60). The proband's mother (IV:9), a carrier, did not experience nystagmus, and her VA was normal.

### Fundus hypopigmentation and foveal hypoplasia

In the present study, fundus examinations were performed in most patients, carriers, and unaffected members of the family ([Table 2](#t2){ref-type="table"}). Significant hypopigmentation of the ocular fundus periphery with normal pigmentation of skin and hair and foveal hypoplasia were observed in the proband ([Figure 2A](#f2){ref-type="fig"}), while his mother ([Figure 2B](#f2){ref-type="fig"}) and his uncle ([Figure 2C](#f2){ref-type="fig"}) did not exhibit such symptoms.

###### Summary of clinical features of some affected males and carriers.

  **ID\# patients**   **Gender**   **Iris hypopigmentation**   **Albinotic fundus**   **Fundus hypopigmentation**   **Fundus foveal hypoplasia**   **Nystagmus**
  ------------------- ------------ --------------------------- ---------------------- ----------------------------- ------------------------------ ---------------
  V:4                 Male         Mild                        No                     Obvious                       Obvious                        Yes
  III:5               Male         Mild                        No                     Obvious                       Obvious                        Yes
  III:7               Male         Mild                        No                     Obvious                       Obvious                        Yes
  III:9               Male         Mild                        No                     Obvious                       Obvious                        Yes
  III:17              Male         Mild                        No                     Mild                          Obvious                        Yes
  IV:17               Male         Obvious                     No                     Obvious                       Obvious                        Yes
  **Carriers**                                                                                                                                     
  IV:9                Female       Normal                      No                     Normal                        No                             No
  III:12              Female       Normal                      No                     Normal                        No                             No
  II:5                Female       Normal                      No                     Normal                        No                             No

![Fundi photographs. **A**: Fundus of the proband (V4) revealed severe fundus hypopigmentation (blue arrow) and foveal hypoplasia (white arrow). **B**: The fundus of the carrier mother (IV9). **C**: Normal fundus (IV10).](mv-v17-715-f2){#f2}

### Iris hypopigmentation

Compared with an unaffected member ([Figure 3C](#f3){ref-type="fig"}), the proband exhibited mild peripheral iris hypopigmentation, as shown in [Figure 3A](#f3){ref-type="fig"}. As a carrier, his mother did not show peripheral iris hypopigmentation ([Figure 3B](#f3){ref-type="fig"}).

![Iris photographs. **A**: Irises of the proband (V4) revealed mild hypopigmentation (blue arrow). **B**: Irises of the carrier mother (IV9). **C**: Normal irises of an unaffected member (IV10).](mv-v17-715-f3){#f3}

Mutation screening
------------------

The nine patients and the fetus (V:5) were hemizygous for a novel splicing mutation c.658+1G\>T ([Figure 4A,C](#f4){ref-type="fig"}), while carriers were heterozygous for this genotype ([Figure 4B](#f4){ref-type="fig"}) and unaffected members were normal ([Figure 4D](#f4){ref-type="fig"}). The splicing mutation c.658+1G\>T was not found in the 200 unrelated controls.

![Sequencing of GPR143. **A**: Sequence in the proband (V4) showing a novel splicing mutation c.658+1G\>T. **B**: Sequence in the proband\'s mother (IV9) revealing a heterozygous mutation. **C**: The sequencing result of the fetus (V5) hemizygous for the mutant allele. **D**: Sequence in an unaffected male member (III6) hemizygous for the wild type allele.](mv-v17-715-f4){#f4}

Discussion
==========

In 1995, Schiaffino et al. \[[@r3]\] screened the entire *GPR143* coding sequence and detected various mutations in one-third of XLOA patients. To date, more than 99 different mutations of *GPR143*, involved in most exons, have been published \[[@r9]\]. Prior to 2007, XLOA in the Chinese population was infrequently reported \[[@r2]\], and to date, only 11 mutations of *GPR143* have been described in the Chinese population including 3 missense mutations \[[@r2],[@r7],[@r10]\], 1 splicing mutation \[[@r7]\], 6 deletion mutations \[[@r7],[@r11],[@r12]\], and 1 duplication mutation \[[@r13]\]. The 11 mutations were all associated with nystagmus but without ocular albinism (OA). In the present study, the novel mutations of c.658+1G\>T were found to cause CN in a large Chinese family. The cumulated number and ethnic distribution of known mutations will help further study in the pathogenesis of CN.

*GPR143* on chromosome Xp22.3 contains nine exons and encodes a protein of 404 amino acids containing seven putative transmembrane domains and one potential N-glycosylation site using an asparagine at codon 106 \[[@r14]\]. *GPR143* is mainly expressed in skin and retinal pigmented epithelial cells. The GPR143 protein is a G protein-coupled receptor (GPCR) that is embedded in the melanosome membrane \[[@r15]\], with the NH~2~-terminus of the protein in the melanosome lumen and the COOH-terminus in the cytosol.

In the present study, we found a splice site mutation of *GPR143* at the exon-intron 5 boundary (c.658+1G\>T) and in the 5′ consensus donor region for the splicing of intron 5--6. This mutation may lead to two possible effects: the loss of the original splicing donor or the generation of a new splice site. If the original splicing donor disappears, the exon 5 of *GPR143* may be lost, thus leading to the introduction of a stop codon. This creates a truncated protein of 187 amino acids ([Figure 5](#f5){ref-type="fig"}), which is much shorter than the normal full-length protein of 404 amino acids, and it may seriously affect the function of this protein. On the other hand, we searched for potential abnormal splice sites generated by this mutation using [NNSPLICE](http://www.fruitfly.org/seq_tools/splice.html) software \[[@r16]\] and found some possible displaced splice sites. Being used instead of the missing original splice site, the neighboring cryptic splice sites might result in short, erratic sequences ending with a stop codon after the normal sequence. If the abnormal mRNA is actually translated and escapes degradation, the encoded protein will be truncated and dysfunctional.

![Schematic diagram showing a possible result from the novel mutation of GPR143: When the original splicing donor disappears, the exon 5 (bases in red font) is lost, hence introducing a new stop codon and creating a truncated protein of 187 amino acids.](mv-v17-715-f5){#f5}

XLOA, a disorder of melanosome biogenesis leading to congenital and persistent visual impairment in affected males, is characterized by CN, reduced visual acuity, hypopigmentation of the iris pigment epithelium and the ocular fundus, and foveal hypoplasia \[[@r17]\]. XLOA is a non-progressive disorder, and visual acuity remains stable throughout life. Nystagmus has been reported in ocular albinism patients with mutations of *GPR143* and is thought to be a secondary phenotype in these patients \[[@r18]\]. However, one of the classical OA phenotypes, ocular albinism, has rarely been observed in patients with *GPR143* mutations. Fang et al. \[[@r7]\] found a similar splicing mutation c.658+1G\>A in a family with XLOA; however, the patients' phenotypes differed from those of our patients. While fundus hypopigmentation existed in our proband but not in theirs, both showed mild iris hypopigmentation. On the contrary, fundus hypopigmentation appeared in their carriers but not in ours. It is still unclear why these two mutations at the same locus (c.658+1G\>T and c.658+1G\>A) in *GPR143* cause different phenotypes. It is possible that the new splice site generated by these two mutations will result in the expression of part intron in the 5′ consensus donor region for the splicing of intron 5--6. Thus, the mutation c.658+1G\>T will introduce a new amino acid p.220Val, while c.658+1G\>A will introduce p.220Asp. Different amino acids may lead to different protein structures and eventually produce different phenotypes.

The role of *GPR143* in the development of the visual system is currently poorly understood \[[@r19]\]. In the present study, we identified a novel causative mutation of *GPR143* and offered a reliable prenatal genetic diagnosis in a five-generation Chinese family with XLOA. Our findings both expand the mutation spectrum of *GPR143* and provide data elucidating the diverse and variable effects of *GPR143* mutations.
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